{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCG+vaccine&page=2",
    "query": {
      "intervention": "BCG vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 151,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCG+vaccine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCG+vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T07:04:53.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00607230",
      "title": "Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2007-11",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00607230"
    },
    {
      "nct_id": "NCT01438112",
      "title": "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Transitional Cell Carcinoma",
        "Bladder Cancer",
        "Carcinoma in Situ",
        "Carcinoma in Situ Concurrent With Papillary Tumors"
      ],
      "interventions": [
        {
          "name": "CG0070 Adenovirus Vector",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Arm: Quadruple Choice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-03",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2021-04-14",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01438112"
    },
    {
      "nct_id": "NCT02010203",
      "title": "A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "HS-410",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Heat Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2013-12",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 19,
      "location_summary": "Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02010203"
    },
    {
      "nct_id": "NCT06211764",
      "title": "A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "TAR-200",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin C",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2024-04-09",
      "completion_date": "2031-04-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 29,
      "location_summary": "Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06211764"
    },
    {
      "nct_id": "NCT00974818",
      "title": "Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Mitomycin C (MMC)",
          "type": "DRUG"
        },
        {
          "name": "Bacillus Calmette-Guerin (BCG)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2009-09",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2015-11-20",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00974818"
    },
    {
      "nct_id": "NCT06919965",
      "title": "A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "TAR-210",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin C",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2025-09-10",
      "completion_date": "2032-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 27,
      "location_summary": "Sun City, Arizona • Los Angeles, California • Lakewood, Colorado + 23 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06919965"
    },
    {
      "nct_id": "NCT01013623",
      "title": "Stage IV Surgery Versus Best Medical Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage IV Resectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgery plus 2 adjuvant doses of BCG",
          "type": "PROCEDURE"
        },
        {
          "name": "best medical therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Saint John's Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2009-11",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2012-09-26",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01013623"
    },
    {
      "nct_id": "NCT07725796",
      "title": "A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder (Urothelial, Transitional Cell) Cancer",
        "NMIBC",
        "Urothelial Carcinoma Bladder",
        "Urothelial Carcinoma in Situ",
        "Urothelial Carcinoma Recurrent",
        "Urothelial Carcinoma of the Urinary Bladder",
        "Non-Muscle Invasive Bladder Carcinoma",
        "Non-muscle Invasive Bladder Cancer (NMIBC)"
      ],
      "interventions": [
        {
          "name": "UGN-501",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-09-30",
      "completion_date": "2029-08-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 11,
      "location_summary": "Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 8 more",
      "locations": [
        {
          "city": "Queen Creek",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07725796"
    },
    {
      "nct_id": "NCT02311101",
      "title": "Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Neoplasm"
      ],
      "interventions": [
        {
          "name": "Mitomycin C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2012-03",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02311101"
    },
    {
      "nct_id": "NCT05843448",
      "title": "IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 0is Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "PD-L1/IDO Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-04-19",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-02T07:04:53.855Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05843448"
    }
  ]
}